A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Trial Profile

A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2014

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Topotecan
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 04 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Aug 2013 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top